U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07081646) titled 'A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis' on July 07.
Brief Summary: Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
Study Start Date: Oct. 15, 2025
Study Type: INTERVENTIONAL
Condition:
Relapsed AL Amyloidosis
Refractory AL Amyloidosis
Light Chain Amyloidosis
Amyloidosis
Intervention:
DRUG: AZD0120
Participants will receive AZD0120 via intravenous (IV) infusion.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Al...